Add hydrochlorothiazide, how about the market of these antihypertensive preparations?

At present, the common Chinese and Western medicine compound preparations (i.e Chinese patent medicines containing western medicine ingredients) approved for production in China include anti cold drugs containing paracetamol and chlorpheniramine, antitussive and antiasthmatic drugs containing ephedrine, hypoglycemic drugs containing glibenclamide, and antihypertensive drugs containing hydrochlorothiazide, etc Hypertension is a common disease in the world, and it is also the main risk factor of stroke, heart failure and renal failure Hydrochlorothiazide (c7h8cln3o4s2) is one of the representatives of six kinds of antihypertensive drugs (diuretics, β - receptor blockers, calcium antagonists, ACE inhibitors, ang Ⅱ receptor antagonists, α - receptor blockers) It was found and successfully synthesized in 1957 when the sulfonamides were developed According to the case report of the national adverse drug reaction monitoring center, when the Chinese and Western medicine compound preparation is used in clinic, it is easy for the patients to be used as pure Chinese medicine preparation and the phenomenon of taking medicine in excess of Western medicine ingredients occurs, and the adverse reactions of Western medicine ingredients are also easy to be ignored High dose administration of hydrochlorothiazide can cause obvious metabolic disorder, which may cause hyperglycemia and glycosuria in diabetic patients and other susceptible patients, and hyperuricemia and gout in some patients Taking hydrochlorothiazide for a long time will bring potential harm to human body, such as increasing the risk of renal cell carcinoma and colon cancer (young patients should be careful when choosing long-term treatment) In addition, hydrochlorothiazide is forbidden in Addison's disease patients; hydrochlorothiazide is related to the occurrence of acute porphyria, which is not safe for patients with existing porphyria The hypokalemia caused by hydrochlorothiazide can also increase the toxicity of digitalis glycoside Therefore, the drug containing hydrochlorothiazide should be used in strict accordance with the instructions, and overdose should be avoided At present, the Chinese and Western medicine compound antihypertensive preparations officially registered and approved to add hydrochlorothiazide include maijun'an tablet (Sinopharm, Sinopharm group), antihypertensive pill, Luoji antihypertensive tablet and Zhenju antihypertensive tablet (as shown in Table 1) The four antihypertensive preparations are prescription drugs (Rx), of which Zhenju antihypertensive tablet accounts for the largest market share Table 1: data source of Chinese and western compound antihypertensive preparations added with hydrochlorothiazide: intelligence data Next, we will analyze the market winning situation of these four antihypertensive preparations one by one: 1 Maijunan tablet Maijun'an tablet is the exclusive variety of Sinopharm group, which has been included in the national medical insurance class B, medical insurance class B in 23 provinces, cities and autonomous regions such as Shanghai and Guangdong, and medical insurance class A in Beijing; it was included in the national low-cost drug catalog in 2014 and low-cost drug catalog in Jiangsu Province in 2015 (2015) Since 2008, maijun'an tablet has won the bid in 16 provinces, cities and autonomous regions including Beijing, Hebei, Zhejiang, Anhui, etc in recent two years, it has won the bid in 5 provinces and cities including Shanghai, Hainan, Hubei, Yunnan, Shanxi, etc (as shown in Table 2) Table 2: bid winning data of maijun'an tablet in 2015 and the first half of 2016: Pharmaceutical intelligence data 2 There are two pharmaceutical companies that have obtained the approval for the production of antihypertensive pill, namely Tianjin ZHONGXIN PHARMACEUTICAL (longshunrong pharmaceutical factory) and Jianmin Pharmaceutical But since 2009, only Tianjin ZHONGXIN PHARMACEUTICAL (longshunrong pharmaceutical factory) has won the bid Hypotensive pill was included in medical insurance class B by Hebei Province and Tianjin city, and also included in the list of low-cost drugs by Hebei Province and Tianjin city in 2014 From 2009 to 2013, the step-down wind shelter tablet won the bid in Hebei, Tianjin, Shandong and other six provinces, but there is no record of winning the bid since 2014 (as shown in Table 3) Table 3: data source of bid winning of antihypertensive pill over the years: Yaozhi data 3 Luoji antihypertensive tablet There are 4 pharmaceutical enterprises that have obtained the approval for Luoji antihypertensive tablet production, including Jilin Yatai star pharmaceutical, Tonghua Renmin pharmaceutical, Jilin Longtai pharmaceutical and Hubei Minkang pharmaceutical However, since the approval, only 3 manufacturers have won the bid, including Jilin Yatai star pharmaceutical, Tonghua Renmin pharmaceutical and Jilin Longtai pharmaceutical Hubei Minkang pharmaceutical has never won the bid Luoji antihypertensive tablet has not been included in the medical insurance of any province Jilin Yatai star Pharmaceutical Co., Ltd has won the bid in seven provinces and cities including Guangdong, Jiangxi and Hebei, and Tonghua Renmin Pharmaceutical Co., Ltd and Jilin Longtai Pharmaceutical Co., Ltd have won the bid in Liaoning and Guangdong respectively Since 2013, none of the three manufacturing enterprises has won the bid (as shown in table 4) Table 4: data sources of winning the bid of Luoji hypotensive tablet over the years: Pharmaceutical intelligence data 4 There are 28 varieties and 118 product specifications of Zhenju hypotensive tablet, and 28 pharmaceutical enterprises such as leiyunshang Pharmaceutical Co., Ltd., Yabao Pharmaceutical Co., Ltd., Northeast Asia Pharmaceutical Co., Ltd of Jilin Province and Shanghai shikangte Pharmaceutical Co., Ltd have obtained production approval documents At present, it has been included in the national medical insurance category B, medical insurance category B of 23 provinces, cities and autonomous regions such as Shanghai and Guangdong, and medical insurance category A of Beijing; it was included in the national low-cost drug catalog in 2014, and it was included in the low-cost drug catalog of Jiangsu Province in 2015 (2015 version) Zhenju hypotensive tablet has won the bid in 26 provinces, cities and autonomous regions such as Beijing, Anhui and Zhejiang since 2007, and successfully won the bid in Chongqing, Hubei and Hainan in the first half of 2016 (as shown in Table 5) Since 2007, the top 3 manufacturers in the bid winning area of Zhenju hypotensive tablet are Jiangsu Yunyang Group Pharmaceutical Co., Ltd (21), Jiangsu Zhongxing Pharmaceutical Co., Ltd (21), Shanxi Yabao Pharmaceutical Group (21), Zhejiang deende Pharmaceutical Co., Ltd (18), Shanghai shikangte Pharmaceutical Co., Ltd (17) and Jiangxi Nanchang Sanghai pharmaceutical factory (17) Table 5: Zhenju Hypotensive Tablets won the bid in the first half of 2016 data source: Yaozhi data note: the intellectual property rights of the above articles belong to yaozhi.com If you need to reprint, please indicate the source and the link of this article.